Detalles de la búsqueda
1.
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
Cancer
; 129(12): 1885-1894, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36951119
2.
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
Clin Lymphoma Myeloma Leuk
; 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38493059
3.
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation.
Cancers (Basel)
; 16(7)2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611035
4.
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Leuk Lymphoma
; 64(14): 2225-2235, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37740588
5.
Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era.
Cancers (Basel)
; 14(17)2022 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36077782
6.
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms.
Front Oncol
; 12: 923809, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35774119
7.
Anti-spike antibody response to the COVID vaccine in lymphoma patients.
PLoS One
; 17(12): e0266584, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36454941
8.
Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Hemasphere
; 6(6): e719, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35747844
Resultados
1 -
8
de 8
1
Próxima >
>>